“The majority of adverse reactions were mild and resolved within two days of vaccination,” the MHRA noted.
“The incidence and severity of adverse reactions were similar after the first and second doses.”
Valneva “appeared less reactogenic than Vaxzevria [the Oxford AstraZeneca vaccine]” in participants aged 30 and older.
The new Covid vaccine, Valneva, is given intramuscularly in two 0.5ml doses, with the second dose administered at least 28 days after the first dose.
